Third-quarter earnings call, November 6, 2026: Q3 beat, FY26 raised, first look at 2027

Mettler-Toledo reported third-quarter sales of $1.1 billion, up 6% in both U.S. dollars and local currencies, with adjusted EPS of $12.57, up 13%. The more consequential news was the initial 2027 outlook: local currency sales growth of approximately 5% and adjusted EPS of $52.50 to $53.50, or 10% to 12% growth. For the fourth quarter, the company guides to roughly 5% local currency growth and adjusted EPS of $14.84 to $15.04. Full-year 2026 adjusted EPS is now forecast at $47.70 to $47.90, up 12%, and local currency sales growth has been narrowed to approximately 5% from 4% to 5%, with organic growth of 4%. The guidance excludes tariff refunds.

2027 Guide Is Built on Maintenance Assumptions, With Several Upside Levers Excluded

Management was explicit that the 2027 outlook does not bank on the themes that dominated the call. CFO Shawn Vadala said the AI and automation opportunity is "not like we've built anything meaningful into our guidance for next year. I view it more as upsides." On onshoring and data center demand, he said both are "very much upside to our guidance." The company also has not assumed an acceleration in the instrument replacement cycle, despite what Vadala described as good activity in analytical instruments and lab balances "for at least a couple of quarters in a row," following the heavy sales of 2021 and 2022.

The 5% growth breaks down into just over 2% from price, above the typical 2% baseline because of mid-2026 pricing actions, and roughly 3% from volume. By division, Laboratory is guided to mid- to high single digits, core Industrial to mid-single digits, product inspection to low to mid-single digits and Food Retail to low single digits. By region, the Americas are expected to grow mid- to high single digits, Europe low single digits and China mid-single digits. Vadala said backlog covers only about 1.5 months at any time, which limits visibility and explains the conservative framing.

China: Tracking About 10% for 2026, Guided to Mid-Single Digits Next Year

China grew 13% in the quarter, with Industrial up in the mid-teens and Lab at a very high single-digit rate. Management expects mid-teens growth in both businesses in the fourth quarter. That puts full-year China growth near 10%, well above the low-single-digit growth the company originally guided, as one analyst noted. Vadala described the recovery as more gradual than spiky, starting in Industrial and now extending into Lab, with pharma standing out.

The 2027 China guide of mid-single digits, which is mid- to high single digits for Lab and low to mid-single digits for Industrial, reflects tougher second-half comparisons rather than a change in demand. Vadala cautioned that "things in China, in particular, can change very quickly," but added that "this probably looks like there's more upside there than downside." China is roughly 16% to 17% of sales, and emerging markets outside China are another 17%, so more than one-third of the business now sits in faster-growing regions. Management is also considering incremental investment in Southeast Asia, India and Korea after its budget tour.

Margins: Operating Leverage Expected, Gross Margin Cautious

Third-quarter gross margin was 59.8%, up 60 basis points on price, lower tariff rates and volume, partly offset by higher material and transportation costs. Adjusted operating margin was 30.5%, up 40 basis points. For 2027, Vadala guided to about 70 basis points of operating margin expansion at the midpoint and about 90 basis points at the high end. Gross margin is expected to be "flattish, maybe up slightly," with management watching inflation and assuming tariffs revert to the prior IEEPA rates. Management declined to size the third-quarter material and transportation headwind, saying only that it is factored into the fourth quarter and 2027 and that mitigation actions are being prepared.

Mix should help modestly because Lab, the higher-margin division, is growing faster than the others, and liquid handling is among the company's better-margin businesses. 2027 free cash flow is expected at about $950 million, up 8% per share, with an equal amount of share repurchases. The tax rate is forecast to fall to 18% from 19%. Year-to-date free cash flow of $652 million was held back by tax payments that were $72 million higher than last year.

Laboratory: R&D Demand Joins Bioprocessing and QA/QC

Laboratory sales rose 6%. Management described a sequential broadening of demand: bioprocessing earlier in the year, quality labs in the second quarter and now research, where liquid handling and pipettes grew strongly after several subdued years. Biotech had been under pressure for several quarters, and pipettes are the company's main exposure to it. Vadala said it was "a great one-two punch" of market recovery and new products, including an electronic pipette and PFAS-free low-retention tips, though he conceded it is hard to separate the two effects. Hot segments such as semiconductors, batteries and GLP-1 also contributed.

AI and Self-Driving Labs: Early Innings, With a Data Layer Strategy

Asked about lab-in-the-loop AI, CEO Patrick Kaltenbach positioned Mettler as a supplier of sensors, instruments and a connectivity layer rather than AI models. He said customers want "an open environment and a data aggregation layer that they can plug into and drive then their experiments using their own AI approaches." LabX, the company's lab software, connects to nearly its entire instrument fleet, and Mettler typically covers about 40% of the bench in a QA/QC lab. He cited battery electrolyte optimization and pharma drug discovery as active use cases and said the company already has several accounts. He called it "still early innings," and no revenue contribution is quantified. Investor day on Monday is expected to include a practical demonstration.

Industrial and Product Inspection: Strong Quarter, Tougher Fourth-Quarter Comparisons

Industrial sales rose 6%, with core Industrial up 5% on top of 10% growth a year ago, led by automation and digitalization, and product inspection up 8%. The company introduced an AI-enabled image recognition package for its X-ray systems and a new weighing transmitter. Vadala guided product inspection to roughly flat in the fourth quarter, citing double-digit growth in both of the prior two fourth quarters and project timing, and he guided the 2027 range conservatively. Kaltenbach said the company does not expect "really high single digit" growth from food markets and is focused on share gains through its mid-market strategy and new high-end products.

Food Retail fell 2% on project timing, particularly in the Americas, and is guided down mid-single digits in the fourth quarter against a roughly 19% comparison. Chemicals have improved from a soft first quarter but remain weaker than pharma.

Europe and the Americas: Soft Europe, Onshoring Is a 2027 Back-Half Story

Europe grew 2% and the Americas 3%, the latter against 9% a year ago. Management described Europe as the region it is watching most closely, citing energy costs, trade disputes and pharma investment concentrated outside the region. Lab in Europe is running at about a mid-single-digit rate, with the other businesses more exposed to the macro.

On U.S. onshoring, Kaltenbach said lead activity and system alerts are "really encouraging," but new pharma facilities typically take two to five years to generate meaningful demand. He expects a contribution toward the second half of 2027 and beyond and called it "a stronger and longer term wave," with only limited revenue so far. Data centers are a small revenue contributor, though a growth opportunity through ultrapure water and cooling system sensors. Management said many projects are already under construction and did not expect the U.S. election to alter the trajectory, while acknowledging, "we don't have a crystal ball."